Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (TSE:ONC)
TSX:ONC
Earnings Data
Report Date
May 02, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 07, 2025
|% Change Since: -21.30%
|Next Earnings Date:May 02, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and promising business development efforts, particularly in breast and gastrointestinal cancers. However, financial challenges, leadership transitions, and regulatory uncertainties pose notable concerns.Company Guidance
The recent conference call from Oncolytics Biotech Inc. provided a comprehensive update on the company's 2024 performance and future guidance. The call highlighted significant progress in the development of pelareorep (PELA), particularly its potential in HR-positive HER2-negative metastatic breast cancer, with plans to initiate a Phase 2 study involving 180 patients. The trial aims to establish a progression-free survival (PFS) endpoint within two years, supporting an accelerated approval submission. The BRACELET-1 study showed a clinically meaningful advantage of more than 12 months in overall survival for patients on PELA combination therapy compared to monotherapy. The call emphasized the promising initial safety and efficacy data from the goblet study in pancreatic and anal cancers, including a 33% objective response rate in relapsed anal cancer and financial backing from PanCAN with a $5 million grant. Financially, the company recorded a net loss of $31.7 million in 2024, with cash and equivalents at $15.9 million by year-end. Looking forward, the company is actively searching for a new CEO and is optimistic about PELA's broad potential across breast, pancreatic, and anal cancers, estimating a $2.4 billion market opportunity in the U.S. and Europe by 2033.BRACELET-1 Breast Cancer Study Exceeds Expectations
The final data from the BRACELET-1 breast cancer study not only met but exceeded expectations, showing a marked statistically significant near doubling of median overall survival in HR-positive HER2-negative metastatic breast cancer.
Positive Results in Gastrointestinal Tumors
Initial safety and efficacy data in both pancreatic and anal cancers are positive. A 33% objective response rate was reported from the goblet cohort four in relapsed anal cancer, including a complete response lasting more than 15 months.
Promising Business Development and Collaborations
Ongoing business development discussions have been positive, with pelareorep showing potential in breast, pancreatic, and anal cancers. Collaborations with GCAR and PanCAN continue to progress, with a $5 million grant from PanCAN funding goblet cohort five.
Robust Financial Management
As of December 31, 2024, the company reported $15.9 million in cash and cash equivalents, with net cash used in operating activities slightly reduced from the previous year.
---
TSE:ONC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TSE:ONC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 07, 2025 | C$1.08 | C$0.99 | -8.33% |
| Nov 12, 2024 | C$1.49 | C$1.55 | +4.03% |
| Aug 01, 2024 | C$1.48 | C$1.40 | -5.41% |
| May 09, 2024 | C$1.69 | C$1.59 | -5.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Oncolytics Biotech (TSE:ONC) report earnings?
Oncolytics Biotech (TSE:ONC) is schdueled to report earning on May 02, 2025, TBA Not Confirmed.
What is Oncolytics Biotech (TSE:ONC) earnings time?
Oncolytics Biotech (TSE:ONC) earnings time is at May 02, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:ONC EPS forecast?
TSE:ONC EPS forecast for the fiscal quarter 2025 (Q1) is -0.1.
---